- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
                        查看更多
                        
                    
                左西孟旦治疗难治性心力衰竭有效性和安全性探讨
                    左西孟旦治疗难治性心力衰竭有效性和安全性探讨
    [摘要] 目的 对难治性心力衰竭患者在常规药物治疗的基础上加用左西孟旦,探讨左西孟旦的有效性和安全性。方法 将难治性心力衰竭患者108例随机分为观察组52例和对照组56例,对照组患者予以常规药物治疗(如利尿剂、地高辛等),观察组患者予以常规治疗的同时加用左西孟旦静脉注射,两组均予以抗感染、限盐、限水、纠正诱发因素等基础治疗。观察两组患者的临床症状改善情况、左室射血分数以及不良反应的发生率。结果 观察组患者的有效率(40.4%;25.0%)及总有效率(86.6%;60.7%)均显著高于对照组(P0.05),无效率(13.4%;39.3%)显著低于对照组(P0.05);观察组与对照组治疗后与治疗前相比,左室射血分数均有提高,但观察组提高的幅度明显高于对照组(P0.05)。结论 左西孟旦可有效提高难治性心力衰竭患者的射血分数,具有较好的有效性和安全性。 
  [关键词] 左西孟旦;心力衰竭;有效性 
  [中图分类号] R725 [文献标识码] A [文章编号] 1674-0742(2014)05(a)-0011-02 
  [Abstract] Objective To observe the efficacy and safety of levosimendan on the basis of routine drug treatment for patients with refractory heart failure. Methods 108 cases of refractory heart failure patients were randomly divided into the observation group (n=52) and the control group(n=56). Patients in the control group were given routine drug treatment, such as diuretic, digoxin and so on, the observation group patients were given intravenous injection of levosimendan on the basis of the conventional treatment. And both groups were also given the basic treatment such as anti-infection, limitation of salt and water, correcting the inducing factors and so forth. The improvement of clinical symptoms, left ventricular ejection fraction and the incidence of adverse reactions of two groups were observed. Results The effective rate (40.4%; 25.0%) and the total effective rate (86.6%, 60.7%) of observation group were significantly higher than those of control group (P0.05); ineffective rate (13.4%; 39.3%) of observation group was significantly lower than that of control group (P0.05). The left ventricular ejection fraction of both groups increased after treatment compared with that before treatment, but the increase rate of the observation group was significantly higher than that of the control group(P0.05). Conclusion Levosimendan can effectively improve the ejection fraction in patients with refractory heart failure, and has better efficacy and safety. 
  [Key words] Levosimendan; Hea
                 原创力文档
原创力文档 
                        

文档评论(0)